VirTra Reports Third Quarter and Nine Months 2026 Financial Results

VirTra, Inc (VTSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 VirTra Reports Third Quarter and Nine Months 2026 Financial Results CHANDLER, Ariz. — November 12, 2026 — VirTra, Inc . (Nasdaq: VTSI) ( “ VirTra ” or the “ Company ” ), a global provider of judgmental use-of-force and firearms training simulators, reported results f

Original reporting
Published Nov 12, 2026, 9:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$VTSI
Bullish
high confidence
Mentioned
$VTSI
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$VTSIBullishMed
01

Why it matters

The earnings beat and new contracts provide a catalyst for short‑term price appreciation, though execution risk remains.

02

Market read

First‑time earnings disclosure for a micro‑cap defense tech firm with notable contract wins; actionable for traders seeking exposure to niche defense equities.

03

What to watch

Potential delays in government funding and grant timing could slow revenue realization.

Relevance 7/10Novelty 8/10Timing: today, after the earnings release

Background

VirTra is a Nasdaq‑listed provider of use‑of‑force training simulators for law‑enforcement and military customers.

Company-level read

Ticker impact

$VTSIBullishHigh confidence
Context

VirTra reported Q3 2026 earnings with 42% revenue growth, $2.2M net income and new $14M CBP contract.

Expected impact

likely upward pressure as market prices in stronger earnings and new contract pipeline

Evidence & confidence

Revenue and profit jumped year‑over‑year, backlog grew, and a multi‑year $14M CBP award was announced, all fresh disclosures.

Market effects

Strengthens outlook for defense and law‑enforcement training simulators sector.

Positive for U.S. defense contractors and federal spending sentiment.

Limited to niche defense training market, but may boost related tech stocks.

Counterpoint

Despite earnings beat, the company remains small and cash‑flow dependent; future backlog conversion risk could limit upside.

Key entities

  • VirTra, Inc.

    Provider of judgmental use‑of‑force training simulators.

  • U.S. Customs and Border Protection

    Awarded a five‑year sole‑source contract worth up to $14M.

Related articles

$VTSIMed

VirTra Reports Second Quarter and Six Months 2026 Financial Results

VirTra, Inc (VTSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 VirTra Reports Second Quarter and Six Months 2026 Financial Results CHANDLER, Ariz. — August 13, 2026 — VirTra, Inc . (Nasdaq: VTSI) ( “ VirTra ” or the “ Company ” ), a global provider of judgmental use-of-force and firearms training simulators, reported results for

$VTSIMedAI 8/10

VirTra (NASDAQ:VTSI) Trading Down 2.9% – What’s Next?

VirTra (NASDAQ:VTSI) shares fell 2.9% to $3.33 on Monday, after trading as low as $3.22; the session volume of 107,453 shares was up 45% versus the average. Research firms cited mixed views: Lake Street cut its target to $5.00 (buy), while Wall Street Zen and Zacks cut to sell/strong sell. In its May 11 quarter, VirTra reported EPS of -$0.12 and revenue of $3.47M.

$NOKMed

LightCounting:: November 2026 Nokia SReXperts

Nokia hosted its SReXperts/Wavelengths conference in November 2026, focusing on AI's impact on connectivity and its solutions for customers. The company reported strong Q3 2026 earnings, with AI & Cloud sales doubling year-over-year and $1.7 billion in new orders. Nokia expects 25-30% growth in its Optical and IP Networks businesses in 2027. The company aims to help telecom operators adapt to AI-driven changes and capitalize on new opportunities.

$IBRXLow

IBRX Stock Eyes Best Year Ever: Founder Teases 12 Months Of ‘Stealth’ NantWorks Reveals — Cancer Tech, AI Chips And Satellites

ImmunityBio (IBRX) reported a 53% increase in Q3 net product revenue to $48.7M, with 92% growth for the first nine months. The company is testing its drug Anktiva for sepsis and aims to expand FDA approval for bladder cancer. NantWorks, led by Patrick Soon-Shiong, plans a blockchain-based exchange for tokenized securities. IBRX stock has risen 195% over the past year, with bullish retail sentiment on Stocktwits.